Results 11 to 20 of about 53,302 (297)
Botulinum toxin type A therapy for blepharospasm [PDF]
Cochrane Database of Systematic Reviews, 2020 This is an update of a Cochrane Review first published in 2005. Blepharospasm is the second most common form of focal dystonia. It is a disabling disorder, characterised by chronic, intermittent or persistent, involuntary eyelid closure, due to spasmodic contractions of the orbicularis oculi muscles.
Duarte, GS +7 more
semanticscholar +6 more sources
Botulinum toxin type A versus botulinum toxin type B for cervical dystonia [PDF]
Cochrane Database of Systematic Reviews, 2016 This is an update of a Cochrane review first published in 2003. Cervical dystonia is the most common form of focal dystonia and is a disabling disorder characterised by painful involuntary head posturing. There are two available formulations of botulinum toxin, with botulinum toxin type A (BtA) usually considered the first line therapy for this ...
Duarte, GS +7 more
semanticscholar +9 more sources
Botulinum toxin type A for facial wrinkles
Cochrane Database of Systematic Reviews, 2021 Botulinum toxin type A (BontA) is the most frequent treatment for facial wrinkles, but its effectiveness and safety have not previously been assessed in a Cochrane Review.To assess the effects of all commercially available botulinum toxin type A products for the treatment of any type of facial wrinkles.We searched the following databases up to May 2020:
Cristina Pires, Camargo +6 more
openaire +3 more sources
Mechanisms of Botulinum Toxin Type A Action on Pain [PDF]
Toxins, 2019 Already a well-established treatment for different autonomic and movement disorders, the use of botulinum toxin type A (BoNT/A) in pain conditions is now continuously expanding. Currently, the only approved use of BoNT/A in relation to pain is the treatment of chronic migraines. However, controlled clinical studies show promising results in neuropathic
Matak, Ivica +3 more
openaire +7 more sources
Toxins, 2021 The differences in analgesic effects of botulinum toxin type A were compared in 28 patients with trigeminal neuralgia, 53 patients with myofascial temporomandibular disorders, and 89 patients with the jaw closing oromandibular dystonia. The patients were
Kazuya Yoshida
doaj +2 more sources
Cephalalgia, 2023 Background This systematic review focuses on chronic migraine patients with medication overuse headache using, respectively, topiramate, botulinum toxin type A, and human monoclonal antibodies targeting calcitonin gene-related peptide or its receptor ...
Samita Giri +4 more
semanticscholar +1 more source
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A
Drugs, 2021 Botulinum toxin type A (BoNTA) products are widely used for therapeutic and aesthetic indications, but there is a need for longer-lasting treatments that maintain symptom relief between injections and reduce the frequency of re-treatment ...
N. Solish +5 more
semanticscholar +1 more source
Cephalalgia, 2021 Background The approval of monoclonal antibodies for prevention of migraine has revolutionized treatment for patients. Oral preventatives are still considered first line treatments as head-to-head trials comparing them with antibodies are lacking ...
Florian Frank +3 more
semanticscholar +1 more source
Toxins, 2021 Unilateral peripheral facial nerve palsy jeopardizes quality of life, rendering psychological consequences such as low self-esteem, social isolation, anxiety, and depression.
Carla de Sanctis Pecora, D. Shitara
semanticscholar +1 more source
Scientific review of the aesthetic uses of botulinum toxin type A
Archives of Craniofacial Surgery, 2021 Botulinum toxin type A (BoNT-A), onabotulinumtoxinA (Botox) was approved by the United States Food and Drug Administration for temporary improvement of glabellar lines in patients 65 years and younger in 2002, and has also been used widely for aesthetic ...
M. Park, K. Ahn
semanticscholar +1 more source